Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 3 4Phase 1 4Phase 1/2 2Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Lung Neoplasms 4Leukemia, Myeloid, Acute 4Fallopian Tube Neoplasms 4Colorectal Neoplasms 4Colonic Neoplasms 4Rectal Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Oropharyngeal Neoplasms 3Myelodysplastic Syndromes 3Leukemia 3Mouth Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Gliosarcoma 2Carcinoma, Ovarian Epithelial 2Carcinoma 2Anemia, Refractory, with Excess of Blasts 2Adenocarcinoma of Lung 2Warts 1Vasculitis 1Urinary Bladder Neoplasms 1Spinal Cord Neoplasms 1Sarcoma, Synovial 1Sarcoma, Clear Cell 1Sarcoma, Alveolar Soft Part 1Sarcoma 1

Interventions

Taxes 1Specimen Handling 1Ramucirumab 1Paclitaxel 1Nivolumab 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × NIH × Adenocarcinoma Of Esophagus × Clear all
NCT06203600 2026-05-26

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
224 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡